当前位置：首页 SCI期刊 SCIE期刊医学中科院4区 JCRQ2 期刊介绍(非官网)

Cancer Biology & TherapySCIE

国际简称：CANCER BIOL THER 参考译名：癌症生物学与治疗

中科院分区
4区
CiteScore分区
Q1
JCR分区
Q2

基本信息：: ISSN：1538-4047; E-ISSN：1555-8576; 是否OA：未开放; 是否预警：否; TOP期刊：否

出版信息：: 出版地区：UNITED STATES; 出版商：Landes Bioscience; 出版语言：English; 出版周期：Monthly; 出版年份：2002; 研究方向：医学-肿瘤学

评价信息：: 影响因子：4.4; H-index：101; CiteScore指数：7; SJR指数：0.914; SNIP指数：0.688

发文数据：: Gold OA文章占比：79.27%; 研究类文章占比：93.83%; 年发文量：81; 自引率：0; 开源占比：0.4241; 出版撤稿占比：0.0090...; 出版国人文章占比：0.55; OA被引用占比：0.1635...

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介Cancer Biology & Therapy期刊介绍

Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.

期刊简介Cancer Biology & Therapy期刊介绍

《Cancer Biology & Therapy》自2002出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间：约2.3月
医学
ONCOLOGY
SCIE
中科院4区
非预警

Cite Score数据（2024年最新版）Cancer Biology & Therapy Cite Score数据

CiteScore：7
SJR：0.914
SNIP：0.688

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q1	94 / 404	76%
大类：Medicine 小类：Pharmacology	Q2	90 / 313	71%
大类：Medicine 小类：Cancer Research	Q2	82 / 230	64%
大类：Medicine 小类：Molecular Medicine	Q2	65 / 178	63%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Cancer Biology & Therapy 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	4区	ONCOLOGY 肿瘤学	4区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Cancer Biology & Therapy JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q2	86 / 322	73.4%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q2	98 / 322	69.72%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
CHINA MAINLAND291
USA133
Italy13
India10
Japan9
England8
GERMANY (FED REP GER)6
South Korea6
Brazil4
Poland4

本刊中国学者近年发表论文

1、The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
Author: Sun Y¹, Wang P², Yang W¹, Shan Y¹, Zhang Q¹, Wu H³.

Journal: Cancer Biol Ther. 2019;20(6):729-739. doi: 10.1080/15384047.2018.1529121. Epub 2019 Mar 27.
2、EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
Author: Lei T¹, Zhu X², Zhu K², Jia F¹, Li S¹.

Journal: Cancer Biol Ther. 2019 Mar 31:1-10. doi: 10.1080/15384047.2019.1595276. [Epub ahead of print]
3、Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Author: Zhu X¹, Zhang Q², Wang D¹, Liu C¹, Han B², Yang JM³.

Journal: Cancer Biol Ther. 2019 Mar 31:1-8. doi: 10.1080/15384047.2019.1595282. [Epub ahead of print]
4、Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.
Author: Wang D¹, Qian G¹, Wang J¹, Wang T¹, Zhang L¹, Yang P¹, Lin F¹.

Journal: Cancer Biol Ther. 2019 Apr 12:1-8. doi: 10.1080/15384047.2019.1591675. [Epub ahead of print]
5、The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis.
Author: Zhou Y¹, Yin L², Li H¹, Liu LH¹, Xiao T¹.

Journal: Cancer Biol Ther. 2019 Apr 12:1-8. doi: 10.1080/15384047.2019.1598766. [Epub ahead of print]
6、A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma.
Author: Zhang B¹, Chen M¹, Jiang N¹, Shi K¹, Qian R¹.

Journal: Cancer Biol Ther. 2019 Apr 12:1-9. doi: 10.1080/15384047.2019.1598762. [Epub ahead of print]
7、Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway.
Author: Zhang C¹, Bao C², Zhang X², Lin X², Pan D¹, Chen Y².

Journal: Cancer Biol Ther. 2019 Apr 14:1-10. doi: 10.1080/15384047.2019.1599671. [Epub ahead of print]
8、Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Author: Jing W^1,², Yan W^1,³, Liu Y⁴, Li J^1,³, Yu J^1,³, Zhu H^1,³.

Journal: Cancer Biol Ther. 2019 Apr 14:1-6. doi: 10.1080/15384047.2019.1598760. [Epub ahead of print]